Adaptive Biotechnologies Corporation $ADPT Shares Sold by Pier Capital LLC

Pier Capital LLC lowered its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 63.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 234,848 shares of the company’s stock after selling 400,235 shares during the quarter. Pier Capital LLC’s holdings in Adaptive Biotechnologies were worth $3,814,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Assetmark Inc. lifted its holdings in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the period. Smartleaf Asset Management LLC boosted its stake in Adaptive Biotechnologies by 593.5% during the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock valued at $59,000 after buying an additional 3,371 shares in the last quarter. Caxton Associates LLP bought a new position in Adaptive Biotechnologies during the first quarter valued at about $93,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Adaptive Biotechnologies by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after buying an additional 1,532 shares in the last quarter. Finally, Quadrant Capital Group LLC bought a new position in Adaptive Biotechnologies during the third quarter valued at about $133,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q1 results beat expectations: ADPT reported EPS of -$0.13 vs. consensus -$0.16 and revenue of $70.9M (well above estimates), with revenue up ~35% year-over-year — a near-term fundamental catalyst that supports the rally. Q1 2026 Earnings Call Transcript
• Positive Sentiment: BTIG reaffirmed a “Buy” and kept a $22 price target, implying roughly ~50% upside from current levels — supportive analyst conviction from a firm with a higher PT. BTIG Buy Rating Reaffirmed
• Positive Sentiment: Guggenheim also reaffirmed its “Buy” rating with a $21 target, backing continued upside expectations based on the company’s growth trajectory. Guggenheim Buy Rating Reaffirmed
• Neutral Sentiment: Full earnings-call transcripts and coverage are available for deeper detail on guidance, margin drivers and commercialization progress — useful for investors but not new headline catalysts by themselves. Earnings Call Transcript
• Negative Sentiment: JPMorgan trimmed its price target from $21 to $19 (still an Overweight rating), signaling slightly reduced near-term expectations; that cut partially offsets the positive analyst actions. Price Target Cut to $19 by JPMorgan

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. BTIG Research reaffirmed a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday. Guggenheim reaffirmed a “buy” rating and set a $21.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research note on Friday, February 6th. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Adaptive Biotechnologies Stock Up 1.8%

Shares of NASDAQ ADPT opened at $14.69 on Friday. Adaptive Biotechnologies Corporation has a 12 month low of $8.50 and a 12 month high of $20.76. The company has a market cap of $2.35 billion, a price-to-earnings ratio of -44.52 and a beta of 2.16. The business has a fifty day simple moving average of $14.27 and a 200-day simple moving average of $15.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s revenue was up 35.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.20) earnings per share. As a group, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.5 EPS for the current fiscal year.

Insider Activity

In related news, CEO Chad M. Robins sold 37,263 shares of the stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $15.19, for a total value of $566,024.97. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares of the company’s stock, valued at approximately $33,122,068.42. This represents a 1.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Julie Rubinstein sold 19,037 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $14.23, for a total value of $270,896.51. Following the completion of the sale, the chief operating officer directly owned 377,802 shares of the company’s stock, valued at approximately $5,376,122.46. This represents a 4.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 2,417,168 shares of company stock valued at $34,153,000. Company insiders own 5.70% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.